GlassScriptPhysician profile
Avanthi Doppalapudi
NPI 1508043779
$1,863.63
in general payments reported to CMS, 2019-2025
17 companies · $95.27 in 2025
The $95.27 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $334 · 2021: $227 · 2022: $371 · 2023: $213 · 2024: $279 · 2025: $95.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $512 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.94 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $755.22 | 2019-2025 | Nuzyra |
| Insmed, INC. | $297.62 | 2019-2025 | Arikayce |
| Ferring Pharmaceuticals INC. | $134.40 | 2024 | Rebyota |
| Merck Sharp & Dohme LLC | $129.72 | 2019-2021 | |
| Glaxosmithkline, LLC. | $127.71 | 2022-2023 | Shingrix, Bexsero, Arexvy |
| Abbvie INC. | $92.92 | 2019-2024 | Teflaro, Avycaz, Dalvance |
| Nevro Corp. | $68.20 | 2022 | |
| Novo Nordisk INC | $46.56 | 2022-2024 | Ozempic, Rybelsus |
| Amgen INC. | $42.00 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $37.31 | 2019-2020 | |
| Melinta Therapeutics, LLC | $36.69 | 2019 | |
| Amarin Pharma, INC. | $28.22 | 2019 | |
| Pfizer INC. | $16.29 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $14.90 | 2020 | |
| Mayne Pharma Commercial LLC | $12.63 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $12.22 | 2019 | |
| Allergan, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avanthi Doppalapudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.